Article

Sex and Age Influence on Association of CYP450 Polymorphism with Midazolam Levels in Critically Ill Children

Carmen Flores-Pérez 1,2,†, Janett Flores-Pérez 1, Manuel de Jesús Castillejos López 3,4,*, Juan Luis Chávez-Pacheco 1,†, Karla Miroslava Tejada-Gutiérrez 1, Arnoldo Aquino-Gálvez 4,*, and Luz María Torres-Espíndola 1,*

1 Laboratory of Pharmacology, National Institute of Pediatrics (INP), Mexico City 04530, Mexico
2 Doctorado en Ciencias Biológicas y de la Salud, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana (Doctorate in Biological and Health Sciences, Division of Biological and Health Sciences, Universidad Autónoma Metropolitana), Ciudad de México 04960, Mexico
3 Epidemiological Surveillance Unit, National Institute of Respiratory Diseases, Mexico City 14080, Mexico
4 Molecular Biology Laboratory, National Institute of Respiratory Diseases, Mexico City 14080, Mexico
* Correspondence: araquiga@yahoo.com.mx (A.A.-G.); luzmtorres@gmail.com (L.M.T.-E.)
† Co-first author.

Abstract: Midazolam is a drug that is metabolized by cytochrome P450 (CYP450) enzymes, particularly CYP3A4 and CYP3A5. The present study aimed to determine the sex and age influence on association of CYP450 polymorphism with midazolam levels in critically ill children. Seventy-two DNA samples were genotyped by real-time PCR. Children ≤ five years of age who carry the rs776746 (T) allele in CYP3A5 gene were associated with lower plasma midazolam levels. The concentration median in patients was 0.0 ng/mL, while in patients with the normal (C) allele, it was 438.17 ng/mL (Q25 135.75–Q75 580.24), p = 0.005. The midazolam plasmatic concentration in female patients with the minor (T) allele was 0.0 ng/mL (Q25 0.00–Q75 204.3), while in patients with the normal (C) allele median it was 459.0 ng/mL (Q25 296.9–Q75 789.7), p = 0.002. Analysis of the dominant model for the rs2740574 variant in CYP3A4 revealed a median of 0.38 L/kg (Q25 0.02–Q75 1.5) for the volume of distribution parameter in female patients with the normal T allele, while female patients with the minor C allele showed a median of 18.1 L/kg (Q25 7.5–Q75 28.7) p = 0.02. Our results suggest an altered midazolam metabolism due to the presence the allelic rs2740574 variants of CYP3A4 and rs776746 of CYP3A5, and also the strong influence of age and sex.

Keywords: midazolam; cytochrome P-450 CYP3A; sex; pharmacokinetics; critically ill; pediatrics

1. Introduction

Midazolam is a benzodiazepine used at the Pediatric Intensive Care Units, from premedication to maintenance of general anesthesia, mainly for effects such as sedation, hypnosis, decreased anxiety, and anterograde amnesia during diagnostic or therapeutic procedures [1,2]. Midazolam is mainly a substrate of CYP3A, CYP3A4, and CYP3A5. Regarding CYP3A4*1L001 and CYP3A5*3.001 polymorphisms (legacy CYP3A5*3 and CYP3A4*1B, respectively), one study reported no significant differences in the pharmacokinetic parameters of midazolam between Caucasian and African American healthy volunteers [3], however, a recent study in Mexican critical pediatric patients found that patients carrying the allelic rs776746 variant in CYP3A5 had increased plasma midazolam levels three hours after infusion discontinuation and greater drug clearance [4]. In addition, there are important pharmacokinetic modifications, particularly on drug clearance, due to factors like age, weight, illness state, ethnicity, or genotype [5]. Due to the observed differences in the CYP3A4 expression and activity in the liver and intestine within different age groups, midazolam clearance is lower in children than in adults [6]. The time needed to achieve the clinical effect on children is higher for midazolam than for any other sedative agent [7].
Physiologic differences between males and females can explain the pharmacokinetic variations, which have been described widely [8,9]. Most of the studies have failed to find significant sex differences regarding midazolam metabolism [10,11]. Except for greater clearance in females [12,13], a small sample size was considered. Although it has been proposed that sex differences in the activity of CYP3A4 exist [14,15], current evidence supporting this is limited, non-existent [16], or contradictory [17]. In previous studies of our group, the allelic variants of the CYP450 genes (nine probes in the CYP2B6, CYP2C9, CYP3A4, and CYP3A5 genes) have been analyzed, and an association of toxicity and response to treatment was reported in patients with solid tumors with the allelic CYP3A4 and CYP3A5 variants [18,19], so it was decided to explore them in a cohort of critically ill pediatric patients. Due to the reasons stated before, the aim of the present study was to determine the sex and age influence on association of CYP450 polymorphism with midazolam levels in critically ill children.

2. Materials and Methods

2.1. Patients

This study was approved with number INP-068/2014 by the Research, Biosafety, and Ethics Committee (IRB 00008064) of the National Institute of Pediatrics. This cohort is special because all patients requiring to be treated in both units during the study period were included. All informed consent forms were signed previously by parents or legal guardians.

Pediatric patients 1–17 years old, of any sex, treated in the Pediatric Intensive Care Unit and Emergency Unit and sedation with midazolam through continuous intravenous (IV) infusion, starting at a 200 µg/kg/h (range 200 to 1200 µg/kg/h) rate and then adjusted according to the sedation level during hospitalization, were included. Patients with suspected hepatic or renal failure, who had undergone partial hepatectomy or partial or total nephrectomy, multiple organ failure, hypersensitivity to benzodiazepines, who had been treated with CYP3A4 inhibitors such as omeprazole, erythromycin, or clarithromycin, with blood transfusion during the last 6 months, who had suffered septic shock, or had any type of leukemia, were excluded. The elimination criteria were: incomplete sampling, serious adverse effects during treatment, and acute renal or hepatic dysfunction developed during the study.

Concomitant medications were recorded during the hospital stay and classified as CYP3A4 substrates, inducers, or inhibitors.

2.2. Peripheral Blood and Plasma Samples

Peripheral blood samples (3 mL) were collected in EDTA Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ, USA) and centrifuged for lymphocyte isolation and further DNA extraction. For the pharmacological analysis, three blood samples (3 mL each) were obtained from every patient. The first sample was taken once the treatment with generic midazolam (PiSA Laboratories, Mexico City, Mexico) was started at an initial IV infusion dose of 200 µg/kg/h, and was collected in a heparin Vacutainer tube (Becton Dickinson, Franklin Lakes, NJ, USA). The next two samples were collected at three and twenty-four hours after the end of treatment. All samples were centrifuged for 10 min at 800 × g (Z326K, Hermle, Gosheim, Germany), and plasma was separated and placed in microcentrifuge tubes, labeled, and stored at −80 °C (MDF-U76VC, Panasonic, Osaka, Japan) until analysis.

2.3. Genotyping

Genomic DNA was isolated from peripheral blood leukocytes (n = 72) using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). For genotyping the allelic variants, rs2740574 in CYP3A4 and rs776746 in CYP3A5. Genotype analysis was performed by allelic discrimination assay using TaqMan probes. For each allelic discrimination assay, specific probes labeled with different fluorophores at the 5’ end, VIC for allele 1 and FAM for allele 2 were obtained from Applied Biosystems, with both probes characterized by having a “quencher” (TAMRA) at the 3’ end which, while the probe remains intact,
inhibits fluorescence emission, and a passive signal (ROX) will be used. The PCR reaction 
was carried out as follows in an microtube, and the following was added for 48 samples: 
240 µL of TaqMan PCR Master Mix 2X, 24 µL of 20X of each probe (Applied Biosystems, 
Foster City, CA, USA), and 120 µL of nuclease-free water (Ultra Pure™) DEPC treated 
water, Invitrogen, Carlsbad, CA, USA. Fluorescence for each sample was quantified in a 
StepOne using SDS 2.2.1 software for allelic discrimination (Applied Biosystems, Foster 
City, CA, USA).

Finally, we analyzed the SNPs based on inheritance models: dominant (mutant homo-
zygous plus heterozygous versus normal homozygous) and recessive (mutant homo-
zygous versus heterozygous plus normal homozygous), by sex (male and female), and age 
(≤five and >five years old) stratification.

2.4. Quantification of Midazolam Plasma Levels

The method is simple and reliable by high-performance liquid chromatography 
(HPLC) and requires only a small volume of plasma (200 µL), which has been previously 
validated and published by our group [20].

2.5. Validation Criteria

Analytical validation met the following criteria: selectivity, linearity, reproducibility, 
repeatability, quantification limit, and stability to different conditions according to Offi-
cial Mexican Standard NOM-177-SSA1, 2013 [20], which were under the FDA and EMA 
international guideline for bioanalytical method validation [21,22].

2.6. Reagents

All reagents were analytical or HPLC grade. Midazolam hydrochloride, acetonitrile, 
and diethyl ether were obtained from Sigma (St. Louis, MO, USA), propranolol from 
ICN Biomedicals Inc. (Aurora, OH, USA), potassium dihydrogen phosphate and sodium 
hydroxide from Merck (Darmstadt, Germany), and deionized water was obtained from 
Elix 35/Milli Q water purification system (Millipore, Molsheim, France).

2.7. Equipment and Chromatographic Conditions

A Waters (Milford, MA, USA) chromatographic system with a 515 pump, a 717 au-
tosampler, a 2487 UV detector, and a degasser (Metachem, Torrance, CA, USA) were 
used. Analytical separation was realized in a reversed-phase column Pursuit C18 (5 µm, 
150 × 3.9 mm i.d., Agilent, Santa Clara, CA, USA) maintained at room temperature (25 °C), 
while the autosampler was kept at 4 °C. The mobile phase was 35 mM phosphate buffer 
solution pH 4.4 (adjusted with phosphoric acid) and acetonitrile (70:30 v/v) with an iso-
cratic flow rate (1 mL/min); absorbance was monitored at 220 nm. Data were obtained and 
processed using Empower Pro™ version 2 software (Waters Inc., Milford, MA, USA).

2.8. Extraction Procedure

Midazolam extraction was done with the addition of 3 mL of diethyl ether to 200 µL 
of plasma (alkalinized with 100 µL of a 1 N sodium hydroxide solution). The solution 
was then vortexed for 1 min and centrifuged at 800× g for 10 min. To ease the separation 
of the organic phase, the tubes were frozen at −80 °C for 10 min and then the organic 
layer was decanted to another tube and evaporated at 40 °C under airstream. The dry 
residue was dissolved in a mixture of 190 µL of mobile phase and 10 µL of 50 µg/mL 
propranolol solution as an external standard. Then, 100 µL aliquots were injected into the 
chromatographic system.

2.9. Determination of Pharmacokinetic Parameters

The data were adjusted to one-compartment pharmacokinetic model for calculating 
the pharmacokinetic parameters and the following formulae were considered:
Elimination constant \((ke) = \ln C_p2 - \ln C_p1/t2 - t1\); elimination half-life \((t1/2) = \ln2/ke\); volume of distribution \((Vd) = D/Cp0\) and clearance \((CL) = ke \times Vd\); where \(Cp\) is the plasma concentration, \(t\) denotes time, \(D\) is the dose administered, and \(Cp0\) is the plasma concentration at zero time [23,24].

Once the pharmacokinetic parameters were obtained, stratification by sex (male and female) and age (≤five and >five years) was performed for statistical analysis.

2.10. Statistical Analysis

The median and the interquartile range \((Q_{25} - Q_{75})\) of the midazolam concentrations at three- and twenty-four hours post-infusion were compared between the allelic variants, stratified by sex and age. The Mann–Whitney U test between age, sex groups, and comparison between the presence of allelic variants and midazolam levels was performed. For the comparison of plasma levels of the drug at three- and twenty-four hours, the Wilcoxon test was used. A \(p\)-value < 0.05 indicated a statistically significant association. Variables were stratified by sex (male and female) and age (≤five and >five years old).

For the statistical analysis, SPSS v20.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, USA) was used.

3. Results

3.1. Study Population Characteristics

Eighty-one patients were invited to participate in the study, of whom 72 accepted and met the study criteria and were included by means of an informed consent that they signed. Forty-three of these patients were male and twenty-nine were female. The demographic and clinical data are shown in Table 1.

Table 1. Demographic and clinical data.

| Characteristic                        | Total N (%) |
|---------------------------------------|-------------|
| Number of patients                    | 72 (100)    |
| Sex (male/female)                     | 43/29 (59.7/40.3) |
| Age (years) *                         | 8.5 (1–17)  |
| Weight (kg) *                         | 21.55 (4.7–85) |
| Midazolam dose (µg/kg/h) *            | 200 (50–1200) |
| Main diagnostic                       |             |
| CNS tumor                             | 13 (18.06)  |
| Community-acquired pneumonia          | 11 (15.3)   |
| Epilepsy/Respiratory insufficiency    | 8 (11.1)    |
| Other                                 | 32 (44.5)   |
| Main concomitant drugs                |             |
| Paracetamol a                         | 57 (79)     |
| Buprenorphine b                       | 49 (68)     |
| Omeprazole a                          | 44 (61)     |
| Dexamethasone b,c                     | 22 (30)     |
| Fentanyl b                            | 19 (26)     |

* Data are expressed in median (range); metabolism of CYP3A4: a, minor substrate; b, major substrate; c, weak inducer.

The genotyping analysis was performed on all 72 patients (data not shown), while, for the determination of pharmacokinetic parameters, nine patients were excluded because their clinical status was compromised due to organ failure, seven subjects were eliminated due to death, and one participant did not have a sufficient blood sample, leaving a total of 55 patients, of whom 21 were female and 34 were male.

3.2. Effect of Midazolam Concentrations according to the CYP3A4 and CYP3A5 Genotypes Stratified by Age

The genotype association’s magnitude with the midazolam plasmatic levels was determined through a comparison of the medians of the dominant and recessive inheritance
models for both allelic variants (rs2740574 in CYP3A4 and rs776746 in CYP3A5) stratified by age (≤five and >five years old).

Analysis of the dominant inheritance model showed a statistically significant association for TT+TC in the rs776746 variant in children ≤five years old. After three hours, the midazolam plasma concentration median in patients with normal CC (major) genotype was 438.17 ng/mL (Q<sub>25</sub> 135.75–Q<sub>75</sub> 580.24), while in patients with the TT+TC (minor), the genotype was 0.0 ng/mL (Q<sub>25</sub>0.00–Q<sub>75</sub>0.00), p = 0.005 (Table 2).

### Table 2. Midazolam concentration according to genotype and stratified by age.

| Age (years) | Genotype | N (%) | Midazolam at 3 h | p-Value | Midazolam at 24 h | p-Value |
|-------------|----------|-------|-----------------|---------|-----------------|---------|
|             |          |       | Median (Q<sub>25</sub>–Q<sub>75</sub>) |         | Median (Q<sub>25</sub>–Q<sub>75</sub>) |         |
| ≤five       | CYP3A4/rs2740574 |       |                 |         |                 |         |
|             | Dominant  |       |                 |         |                 |         |
|             | CC+CT     | 21 (91) | 386.61 (191.98–581.24) | 0.2 | 111.49 (0.0–222.9) | 0.9 |
|             | TT        | 2 (9)   | 0.0 (0.0–459)     |         | 0.0 (0.0–0.0)    |         |
|             | Recessive |       |                 |         |                 |         |
|             | CC        | 23 (100)| NC (0.00–487.96)  | NC      | NC (0.00–196.64) | 0.5    |
|             | CT+TT     | 0       | NC               |         | NC (0.00–133.23) |         |
| >five       | CYP3A4/rs2740574 |       |                 |         |                 |         |
|             | Dominant  |       |                 |         |                 |         |
|             | CC+CT     | 5 (16)  | 23.51 (0.00–96.2) | 0.1 | 0.00 (0.00–79.03) | 0.6 |
|             | TT        | 27 (84) | 146.83 (0.00–332.5)|         | 0.00 (0.00–133.23)|         |
|             | Recessive |       |                 |         |                 |         |
|             | CC        | 32 (100)| 119.67 (0.00–332.5)| 0.3 | 0.00(0.00–133.23)| 0.5   |
|             | CT+TT     | 0       | NC               |         | NC (0.00–133.23) |         |
| ≤five       | CYP3A5/rs776746 |       |                 |         |                 |         |
|             | Dominant  |       |                 |         |                 |         |
|             | TT+TC     | 11 (48) | 0.0 (0.00–0.00)  | 0.005 *| 0.00 (0.00–0.00) | 0.5   |
|             | CC        | 12 (52) | 438.17 (135.75–580.24)|         | 0.00 (0.00–196.64)|         |
|             | Recessive |       |                 |         |                 |         |
|             | TT        | 0       | NC               |         | NC (0.00–133.23) |         |
|             | TC+CC     | 23 (100)| 79.52 (0.00–487.96)| NC      | NC (0.00–133.23) |         |
| >five       | CYP3A5/rs776746 |       |                 |         |                 |         |
|             | Dominant  |       |                 |         |                 |         |
|             | TT+TC     | 16 (50) | 27.45 (0.00–206.96) | 0.055  | 0.00 (0.00–89.09) | 0.2   |
|             | CC        | 16 (50) | 276.04 (15.05–370.29)|         | 62.97 (0.00–172.0)|         |
|             | Recessive |       |                 |         |                 |         |
|             | TT        | 2 (6)   | 104.7 (0.00–209.5) | 0.6 | 84.46 (0.00–168.9)| 0.8   |
|             | TC+CC     | 30 (94) | 119.67 (0.00–342.5)|         | 0.00 (0.00–99.1)|         |

* Statistical significance was calculated using the nonparametric Mann–Whitney U test; NC = Not calculable.

After twenty-four hours, patients with the major genotype had a concentration of 0.00 ng/mL (Q<sub>25</sub>0.00–Q<sub>75</sub>196.64), and patients with the minor genotype had a midazolam concentration median of 0.00 ng/mL (Q<sub>25</sub>0.00–Q<sub>75</sub>0.00), p = 0.5. In children older than five years old, no statistically significant association was found.

The recessive inheritance model analysis of the rs2740574 variant showed no association between its presence, midazolam levels, and age (Table 2). No association between the allelic variant, pharmacokinetic parameters, and age was found after analysis with both inheritance models (data not shown).

### 3.3. Effect of Midazolam Concentrations according to the CYP3A4 and CYP3A5 Genotypes Stratified by Sex

The medians of the dominant and recessive inheritance models stratified by (male and female) for both allelic variants (rs2740574 and rs776746) were compared to obtain the genotype association’s magnitude with the midazolam plasmatic levels.

A statistically significant association was found in females with the TT+TC of the rs776746 variant in the dominant inheritance model analysis. After three hours, a median of 459.0 ng/mL (Q<sub>25</sub>296.9–Q<sub>75</sub>789.7) for the midazolam plasmatic concentration was found.
in female patients with the major genotype, while in patients with the minor genotype it was 0.0 ng/mL ($Q_{25}$0.00–$Q_{75}$204.3), $p = 0.002$ (Table 3).

Table 3. Midazolam concentration according to the genotype and stratified by sex.

| Sex     | Genotype | N (%)     | Midazolam at 3 h Median ($Q_{25}–Q_{75}$) | $p$-Value | Midazolam at 24 h Median ($Q_{25}–Q_{75}$) | $p$-Value |
|---------|----------|-----------|-----------------------------------------|-----------|------------------------------------------|-----------|
| Male    | CC+CT    | 6 (17.6)  | 107.7 (0.00–342.6)                      | 0.9       | 0.00 (0.00–195.2)                        | 0.7       |
|         | TT       | 28 (82.4) | 27.4 (0.00–301.3)                       | 0.00      | 0.00 (0.00–133.9)                        | 0.00      |
| Female  | CC+CT    | 1 (5)     | NC                                      | 0.3       | NC                                       | 1         |
|         | TT       | 20 (95)   | 288.4 (0.00–563.6)                      | 0.00      | 0.00 (0.00–133.2)                        | 1         |
| Male    | CC       | 0         | NC                                      | 0.4       | NC                                       | 0.6       |
|         | CT+TT    | 34 (100)  | 39.21 (0.00–322.5)                      | 0.00      | 0.00 (0.00–168.9)                        | 0.3       |
| Female  | CC       | 0         | NC                                      | 0.00      | 1                                        | 0.3       |
|         | CT+TT    | 21 (100)  | 275.6 (0.00–548.0)                      | 0.00      | 0.00 (0.00–99.1)                         | NC        |

*C Statistical significance was calculated using the nonparametric Mann–Whitney U test; NC = Not calculable.

Twenty-four hours post-infusion, female patients with the major genotype showed a concentration of 0.00 ng/mL ($Q_{25}$0.00–$Q_{75}$171.6), and patients with the minor genotype had a midazolam concentration median of 0.00 ng/mL ($Q_{25}$0.00–$Q_{75}$79.0), $p = 0.3$. In male patients, no association was found with either allelic variant (Table 3).

3.4. Effect of CYP3A4 and CYP3A5 Genotypes over the Pharmacokinetic Parameters Stratified by Sex

To determine the genotype association’s magnitude with the midazolam pharmacokinetic parameters, the medians were compared using the dominant and recessive inheritance models for both allelic variants (rs2740574 and rs776746), stratifying by sex (male and female).

Analysis of the dominant model for the rs2740574 variant revealed a median of 0.38 L/kg ($Q_{25}$0.02–$Q_{75}$1.5) for the Vd parameter in female patients with the TT (major) genotype. Meanwhile, female patients with the CC+CT (minor) genotype showed a median of 18.1 L/kg ($Q_{25}$7.5–$Q_{75}$28.7) $p = 0.02$ (Table 4). The dominant model in males found no statistically significant association.

The recessive inheritance model analysis for the rs2740574 variant presented no association among its presence, pharmacokinetic parameters, or sex. This was also the case for the rs776746 variant for both inheritance models between the allelic variant presence, pharmacokinetic parameters, and sex, as no association was found (Table 4).
Table 4. Effect of the allelic variant on the pharmacokinetic parameters of midazolam stratified by sex.

| Sex       | Allelic Variant | ke (h⁻¹) Median (Q₂₅–Q₇₅) p-Value | t ½ (h) Median (Q₂₅–Q₇₅) p-Value | Vd (L/kg) Median (Q₂₅–Q₇₅) p-Value | CL (L/kg/h) Median (Q₂₅–Q₇₅) p-Value |
|-----------|-----------------|----------------------------------|----------------------------------|-----------------------------------|-----------------------------------|
| Male      | CYP3A4*/rs2740574 Dominant | 0.026 (0.12–0.008) 0.7 | 25.2 (5.5–25.7) 0.7 | 5.8 (0.2–6.2) 0.9 | 0.11 (0.03–0.16) 0.5 |
|           | CYP3A4*/rs2740574 Recessive | 0.046 (0.20–0.01) 0.5 | 15.0 (3.3–35.5) 0.4 | 3.3 (0.5–10.5) 0.38 (0.02–1.5) 0.02 * | 1.2 (0.05–2.35) 0.1 |
| Female    | CYP3A4*/rs2740574 Dominant | 0.01 (0.1–0.02) 0.5 | 53.7 (8.45–99) 0.4 | 18.1 (7.5–28.7) 0.38 (0.02–1.5) 0.02 * | 0.01 (0.001–0.06) 0.01 |
|           | CYP3A4*/rs2740574 Recessive | 0.03 (0.2–0.01) 0.4 | 10.9 (6.5–34.6) 0.3 | 3.5 (0.2–9.8) 0.13 (0.02–0.3) 0.018 (0.002–0.049) | 0.10 (0.02–0.3) 0.6 |
| Male      | CYP3A5*/rs776746 Dominant | 0.078 (0.25–0.018) 0.1 | 8.8 (2.7–36.4) 0.3 | 3.3 (0.8–18.0) 0.7 | 0.16 (0.03–0.45) 0.9 |
|           | CYP3A5*/rs776746 Recessive | 0.06 (0.1–0.02) 0.4 | 9.03 (2.6–18.2) 0.3 | 1.00 (0.01–8.40) 0.9 | 0.07 (0.001–0.105) 0.6 |
| Female    | CYP3A5*/rs776746 Dominant | 0.05 (0.08-0.02) 0.2 | 16.2 (3.3–35.6) 0.3 | 0.5 (0.03–1.7) 0.02 | 0.02 (0.001–0.06) 0.018 (0.002–0.049) |
|           | CYP3A5*/rs776746 Recessive | 0.00 (0.08-0.02) 0.1 | 10.9 (6.6–42.1) 0.3 | 0.5 (0.03–1.7) 0.02 | 0.02 (0.001–0.06) 0.018 (0.002–0.049) |

* Statistical significance was calculated using the nonparametric Mann–Whitney U test; NC = Not calculable.

4. Discussion

In the absence of pediatric pharmacokinetic studies to guide the safe and effective use of drugs, pediatric dosing can be directed by knowing anatomic and physiologic factors which help to understand drug disposition in this population [25]. Midazolam may be more effective in children because it has a faster onset of action and shorter duration than other benzodiazepines [26]. Drug disposition in children differs from that of adults due to age, absorption, distribution, metabolism, and excretion [27]. These differences may be due to a smaller intestine and altered permeability; in addition to gastric emptying time, the intestinal transit time, bile fluid production, and blood flow to the intestines and liver may be modified in children [28].

Individual response to drugs is highly variable. It can be regulated by genetic and environmental factors, age, sex, body size, ethnicity, diseases, kidney and liver pathologies, diabetes, and obesity [29].

Females and males may respond differently to the same therapeutic regimen due to sex-specific variations in pharmacokinetics and pharmacodynamic profiles [30–32]. The expression and activity of drug-metabolizing CYP450 enzymes can be affected by many factors, including genetic polymorphisms and sex, leading to changes in drug metabolism and therapeutic effects [33–35].

It is estimated that in human beings there is a 40% pharmacokinetic difference between men and women; women are smaller, have higher body fat content, have less muscle compared to men, and their total body water is lower (~15–20%) [32].

Sex-related differences in pharmacokinetics and pharmacodynamics include noticeable physiologically related differences, such as body fat content and hormonal influence, among others [29]. The possibility of variations in the menstrual cycle and the renal, cardiovascular, and hematomatological systems, which may affect protein binding and volume of distribution, has been studied [30]. Although estrogen appears to affect CYP3A activity in vitro, no menstrual cycle changes have been found in the metabolism of CYP3A substrates in vivo [11,36]. Regarding CYP3A5*3 and CYP3A4*1B polymorphisms, Miao et al. (2009) [3] reported that there were no significant differences in the pharmacokinetic parameters of midazolam. In contrast, we found a sex-related influence on the concentrations and volume of distribution of midazolam (Tables 3 and 4, respectively), where it is shown that females who carry the CYP3A5 rs776746 variant comparing to girls with the normal allele,
showing a decrease in plasma concentrations since three hours after the end of treatment and an increase in the volume of distribution females who carry the CYP3A4 rs2740574 variant comparing to girls with the normal allele.

In women, the volume of distribution of lipophilic drugs is increased [8,37,38], including benzodiazepines such as diazepam [34,35] and midazolam [10]. In the present work, we found that in the dominant model, patients carrying the CYP3A4 rs2740574 (CC+CT) variant had a larger volume of distribution compared to patients with the normal genotype (TT).

The same dose of a lipophilic drug will have a lower serum concentration in a female compared to a male with the same body weight because there is a relatively larger lipophilic compartment in which the drug resides. In our study, we observed that in the dominant model, female patients with the CYP3A5 rs776746 variant (TT+TC) did not show plasma levels of the drug compared to patients with the normal genotype (CC) three hours after the end of treatment.

Most studies have found no significant sex differences in midazolam metabolism [10,11,39,40], except for increased clearance in females [12,13], although this was a small sample size. A study by Wolbold et al. (2003) [41] found that the CYP3A4 mRNA levels were twice as high in the liver of women than in men. A greater clearance mediated by CYP3A4 has been reported in women compared to men [42,43]. Likewise, some reports have proposed to find the sex differences regarding the pharmacokinetic parameters of the CYP3A4 or CYP3A5 substrates; a study realized by Chen et al. (2006) [42], in which sex differences of the midazolam blood concentrations in adults were reported, concluded that women had a higher liver and intestinal enzymatic activity of CYP3A compared to men. Nonetheless, studies showing sex differences with the CYP3A5 variant in children were not found.

Studies have already been realized in adults evaluating the effect of age-related blood and plasma drug concentrations, with contradictory results, however. From seven studies conducted with intravenous midazolam, only five evaluated the age, and, just in one, with men participating, a significantly lower midazolam clearance was found as the age increased [10]. However, one study found women’s clearance decreases as age increases [44], and another two, who tested intravenous midazolam, found no significant differences with age [10,45]. On the other hand, the intravenous use of midazolam without considering sex as a variable for the analysis has been reported, and the age differences in clearance were not significant [46].

This is the first study to show differences in midazolam plasma concentrations in critically ill patients ≤ 5 years old who carry the CYP3A5 rs776746 variant; compared to children with the normal allele, they showed a decrease in plasma concentrations from three hours after the end of treatment, inferring an increase in clearance of the drug, and could require more doses of the drug to remain sedated, and also we could not find age-related differences in clearance because of the small sample size in this group. Some reports mentioned that the pharmacokinetics of xenobiotics could differ widely between children and adults due to physiological differences, metabolism, protein binding, immaturity of enzyme systems, the volume of distribution, and clearance mechanisms [47–50].

Among the limitations of the study was the small sample size, and death and organ failure during follow-up, which made it difficult to determine the pharmacokinetic parameters. Possible adverse reactions with concomitant medications were not reported in the clinical records, and no information was found on the use of assessment scales in this population.

This is a helpful strategy, since the results obtained could lay the foundations for the design of personalized therapeutic schemes, resulting in the best cost–benefit and monitoring of adverse events for different drugs metabolized by CYP3A in the Mexican pediatric and probably in the Latin American population.
5. Conclusions

Our results suggest an altered midazolam metabolism due to the presence of the allelic rs2740574 variants of CYP3A4 and rs776746 of CYP3A5, and the strong influence of age and sex.

In critically ill patients ≤ 5 years old carrying the allelic rs776746 variant in CYP3A5, the plasma concentrations of midazolam decreased at three hours after the end of treatment compared to children with the normal allele. They may require more doses of midazolam to remain sedated.

Females who carry the CYP3A5 rs776746 variant had decreased plasma concentrations three hours after the end of treatment compared to girls with the normal allele, and also showed an increase in the volume of distribution in females who carry the CYP3A4 rs2740574 variant compared to those with the normal allele, and likely could need adjustment of doses of midazolam to achieve the desired effect.

Further studies in larger samples are required to validate these findings and the relevance of these variants in CYP3A4 and CYP3A5 genes.

Author Contributions: Conceptualization, C.F.-P., M.d.J.C.L. and L.M.T.-E.; methodology C.F.-P. and L.M.T.-E.; formal analysis, C.F.-P., M.d.J.C.L. and L.M.T.-E.; writing—original draft preparation, C.F.-P. and L.M.T.-E.; writing—review and editing, J.F.-P., J.L.C.-P., K.M.T.-G. and A.A.-G. All authors have read and agreed to the published version of the manuscript.

Funding: This paper has been supported by Program E022 of the National Institute of Pediatrics.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and this study was approved with number INP-068/2014 by the Research, Biosafety and Ethics Committee (IRB 00008064, approved date is 01/31/2019) of the National Institute of Pediatrics. This board was renewed and approved for use through June 30th, 2025.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: Israel Torres Ramírez de A. for his support in the translation and edition of this article.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Lu, H.B.; Jia, Y.P.; Liang, Z.H.; Zhou, R.; Zheng, J.Q. Effect of Continuous Infusion of Midazolam on Immune Function in Pediatric Patients after Surgery. Genet. Mol. Res. 2015, 14, 10007–10014. [CrossRef]
2. Olkkola, K.T.; Ahonen, J. Midazolam and Other Benzodiazepines. Handb. Exp. Pharm. 2008, 182, 335–360. [CrossRef]
3. Miao, J.; Jin, Y.; Marunde, R.L.; Kim, S.; Quinney, S.; Radovich, M.; Li, L.; Hall, S.D. Association of Genotypes of the CYP3A Cluster with Midazolam Disposition In Vivo. Pharm. J. 2009, 9, 319–326. [CrossRef]
4. Flores-Pérez, C.; Castillejos-López, M.D.J.; Chávez-Pacheco, J.L.; Dávila-Borja, V.M.; Flores-Pérez, J.; Zarate-Castañón, P.; Acosta-Bastidas, M.; Cruz-Escobar, J.; Torres-Espindola, L.M. The Rs776746 Variant of CYP3A5 Is Associated with Intravenous Midazolam Plasma Levels and Higher Clearance in Critically Ill Mexican Paediatric Patients. J. Clin. Pharm. 2021, 46, 633–639. [CrossRef]
5. Altamimi, M.I.; Sammons, H.; Choonara, I. Inter-Individual Variation in Midazolam Clearance in Children. Arch. Dis. Child. 2015, 100, 95–100. [CrossRef] [PubMed]
6. Marçon, F.; Guittet, C.; Manso, M.A.; Burton, I.; Granier, L.A.; Jacqm, P.; Dupont, H. Population Pharmacokinetic Evaluation of ADV6209, an Innovative Oral Solution of Midazolam Containing Cyclodextrin. Eur. J. Pharm. Sci. 2018, 114, 46–54. [CrossRef]
7. Sagarin, M.J.; Chiang, V.; Sakles, J.C.; Barton, E.D.; Wolfe, R.E.; Vissers, R.J.; Walls, R.M. Rapid Sequence Intubation for Pediatric Emergency Airway Management. Pediatr. Emerg. Care 2002, 18, 417–423. [CrossRef]
8. Buchanan, F.F.; Myles, P.S.; Cicuttini, F. Patient Sex and Its Influence on General Anaesthesia. Anaesth. Intensive Care 2009, 37, 207–218. [CrossRef]
9. Campesi, I.; Fois, M.; Franconi, F. Sex and Gender Aspects in Anesthetics and Pain Medication. Handb. Exp. Pharm. 2012, 214, 265–272. [CrossRef]
10. Greenblatt, D.J.; Abernethy, D.R.; Locniskar, A.; Harmatz, J.S.; Limjucu, R.A.; Shader, R.I. Effect of Age, Gender, and Obesity on Midazolam Kinetics. Anesthesiology 1984, 61, 27–35. [CrossRef]
11. Kashuba, A.D.M.; Bertino, J.S.; Rocci, M.L.; Kulawy, R.W.; Beck, D.J.; Nafziger, A.N. Quantification of 3-Month Intraindividual Variability and the Influence of Sex and Menstrual Cycle Phase on CYP3A Activity as Measured by Phenotyping with Intravenous Midazolam. Clin. Pharm. 1998, 64, 269–277. [CrossRef]

12. Greenblatt, D.J.; Loci, M.; A; Scavone, J.M.; Blyden, G.T.; Ochs, H.R.; Harmatz, J.S.; Shader, R.I. Absence of Interaction of Cimetine and Ranitidine with Intravenous and Oral Midazolam. Anesth. Analg. 1986, 65, 176–180.

13. Kinirons, M.T.; O'Shea, D.; Kim, R.B.; Groopman, J.D.; Thummel, K.E.; Wood, A.J.; Wilkinson, C.R. Failure of Erythromycin Breath Test to Correlate with Midazolam Clearance as a Probe of Cytochrome P4503A. Clin. Pharm. 1999, 66, 224–231. [CrossRef]

14. Myles, P.S.; McLeod, A.D.; Hunt, J.O.; Fletcher, H. Sex Differences in Speed of Emergence and Quality of Recovery after Anaesthesia: Cohort Study. BMJ 2001, 322, 710–711. [CrossRef]

15. Apfelbaum, J.L.; Grasela, T.H.; Hug, C.C.; McLeskey, C.H.; Nahrwold, M.L.; Roizen, M.F.; Stanley, T.H.; Thisted, R.A.; et al. Genetic Polymorphism of CYP3A4 Associated with Poor Response to Ifosfamide in Children with Solid Embryonic Tumors. Arch. Med. Sci. 2019, 17, 1–6. [CrossRef]

16. Hoymork, S.C.; Raeder, J.; Grimsmo, B.; Steen, P.A. Bispectral Index, Serum Drug Concentrations and Emergence Associated with Prolonged Time to Awakening. Anesth. Analg. 1993, 77, S10–S14. [PubMed]

17. Miller, J.; Anacta, L.; Cattran, D. Impact of Gender on the Renal Response to Angiotensin II. J. Pharmacol. Exp. Ther. 1993, 261, 864–871. [CrossRef]

18. Espindola, L.M.T.; Castillejos L., 2797, 2001, 55, 278–285. [CrossRef] [PubMed]

19. Torres Espindola, L.M.; Castillejos López, M.D.J.; de Uña Flores, A.; Espinosa, L.R.; Granados, J.; Chávez Pacheco, J.L.; García, M.P.; Ramos Cervantes, M.T.; Bekker Méndez, V.C.; Hernández Doño, S.; et al. Genetic Polymorphism of CYP3A4 Is Associated with Poor Response to Ifosfamide in Children with Solid Embryonic Tumors. Arch. Med. Sci. 2019, 17, 1–6. [CrossRef]

20. Apfelbaum, J.L.; Grasela, T.H.; Hug, C.C.; McLeskey, C.H.; Nahrwold, M.L.; Roizen, M.F.; Stanley, T.H.; Thisted, R.A.; et al. Genetic Polymorphism of CYP3A4 Associated with Poor Response to Ifosfamide in Children with Solid Embryonic Tumors. Arch. Med. Sci. 2019, 17, 1–6. [CrossRef]

21. European Medicines Agency. Guideline on Bioanalytical Method Validation. Available online: http://www.ema.europa.eu/docs/en_GB/document_library//Scientific_guideline/2011/08/WC500109686.pdf (accessed on 2 August 2021).

22. Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry. Available online: https://www.fda.gov/anesthesia-pharmacology/cpd-procedimientos-para-demostrar-que-un-medicamento-es-intercambiable. [CrossRef] [PubMed]

23. Gibraldi, M. Biopharmaceutics and Clinical Pharmacokinetics, 4th ed.; Lea & Febiger: Philadelphia, PA, USA, 1991; Volume 4, ISBN 0-8121-1346-2.

24. rowland, M.; Tozer, T.N. Clinical Pharmacokinetics: Concepts and Applications, 4th ed.; Lea & Febiger: Philadelphia, PA, USA, 1989; Volume 4, ISBN 9780683074048.

25. Abdel-Rahman, S.M.; Kauffman, R.E. The Integration of Pharmacokinetics and Pharmacodynamics: Understanding Dose-Response. Annu. Rev. Pharm. Toxicol. 2009, 49, 111–136. [CrossRef]

26. Salonen, M.; Kanto, J.; Iisalo, E.; Himberg, J.J. Midazolam as an Induction Agent in Children: A Pharmacokinetic and Clinical Study. Anesth. Analg. 1987, 66, 625–628. [CrossRef]

27. van Groen, B.D.; Vaes, W.H.; Park, B.K.; Krekels, E.H.J.; van Duijn, E.; Körgve, L.T.; Maruszak, W.; Grynkiewicz, G.; Garner, R.C.; Knibbe, C.A.J.; et al. Dose-Linearity of the Pharmacokinetics of an Intravenous [14C]Midazolam Microdose in Children. Br. J. Clin. Pharm. 2019, 85, 2332–2340. [CrossRef]

28. Brussee, J.M.; Yu, H.; Krekels, E.H.J.; Palić, S.; Brill, M.J.E.; Barrett, J.S.; Rostami-Hodjegan, A.; de Wildt, S.N.; Knibbe, C.A.J. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. Pharm. Res. 2018, 35, 182. [CrossRef] [PubMed]

29. Farkouh, A.; Riedl, T.; Cezjak, M.; Kautzky-Willer, A. Sex-Related Differences in Pharmacokinetics and Pharmacodynamics of Frequently Prescribed Drugs: A Review of the Literature. Adv. Ther. 2020, 37, 644–655. [CrossRef] [PubMed]

30. Nicolau, J.M.; Espie, P.; Molimard, M. Gender and Interindividual Variability in Pharmacokinetics. Drug Metab. Rev. 2009, 41, 408–421.

31. Harper, K.W.; Collier, P.S.; Dunn, J.W.; Elliott, P.; Halliday, N.J.; Lowry, K.G. Age and Nature of Operation Influence the Pharmacokinetics of Midazolam. Br. J. Anaesth. 1985, 57, 866–871. [CrossRef] [PubMed]

32. Anderson, G.D. Sex and Racial Differences in Pharmacological Response: Where Is the Evidence? Pharmacogenetics, Pharmacokinetics, and Pharmacodynamics. J. Womens Health 2005, 14, 19–29.

33. Booj, L.H. Sex, Age, and Genetics in Anesthesia. Curr. Opin. Anaesthesiol. 2008, 21, 462–466. [PubMed]

34. Greenblatt, D.J.; Divoll, M.; Harmatz, J.S.; Shader, R.I. Oxazepam Kinetics: Effects of Age and Sex. J. Pharmacol. Exp. Ther. 1980, 215, 86–91. [PubMed]

35. Ochs, H.R.; Greenblatt, D.J.; Divoll, M.; Abernethy, D.R.; Feyerabend, H.; Dengler, H.; Diazepam Kinetics in Relation to Age and Sex. Pharmacology 1981, 23, 24–30. [CrossRef]

36. Soldin, O.P.; Chung, S.H.; Mattison, D.R. Sex Differences in Drug Disposition. J. Biomed. Biotechnol. 2011, 2011, 187103. [CrossRef]
37. Jochmann, N.; Stangl, K.; Garbe, E.; Baumann, G.; Stangl, V. Female-Specific Aspects in the Pharmacotherapy of Chronic Cardiovascular Diseases. Eur. Heart J. 2005, 26, 1585–1595. [PubMed]
38. Pleym, H.; Spigset, O.; Kharasch, E.D.; Dale, O. Gender Differences in Drug Effects: Implications for Anesthesiologists. Acta Anaesthesiol. Scand. 2003, 47, 241–259.
39. Thummel, K.E.; Shen, D.D.; Podoll, T.D.; Kunze, K.L.; Trager, W.F.; Bacchi, C.E.; Marsh, C.L.; McVicar, J.P.; Barr, D.M.; Perkins, J.D.; et al. Use of Midazolam as a Human Cytochrome P450 3A Probe: II. Characterization of Inter- and Intraindividual Hepatic CYP3A Variability after Liver Transplantation. J. Pharmacol. Exp. Ther. 1994, 271, 557–566.
40. Nishiyama, T.; Matsukawa, T.; Hanaoka, K. The Effects of Age and Gender on the Optimal Premedication Dose of Intramuscular Midazolam. Anesthesiology 1998, 86, 1103–1108. [CrossRef] [PubMed]
41. Wolbold, R.; Klein, K.; Burk, O.; Nüssler, A.K.; Neuhaus, P.; Eichelbaum, M.; Schwab, M.; Zanger, U.M. Sex Is a Major Determinant of CYP3A4 Expression in Human Liver. Hepatology 2003, 38, 978–988. [CrossRef]
42. Chen, M.; Ma, L.; Drusano, G.L.; Bertino, J.S.; Nafziger, A.N. Sex Differences in CYP3A Activity Using Intravenous and Oral Midazolam. Clin. Pharm. 2006, 80, 531–538. [CrossRef]
43. Cotreau, M.M.; von Moltke, L.L.; Greenblatt, D.J. The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates. Clin. Pharm. 2005, 44, 33–60.
44. Fleishaker, J.C.; Pearson, L.K.; Pearson, P.G.; Wienkers, L.C.; Hopkins, N.K.; Peters, G.R. Hormonal Effects on Tirilazad Clearance in Women: Assessment of the Role of CYP3A. J. Clin. Pharmacol. 1999, 39, 260–267. [CrossRef]
45. Avram, M.J.; Fragen, R.J.; Caldwell, N.J. Midazolam Kinetics in Women of Two Age Groups. Clin. Pharmp. 1983, 34, 505–508. [CrossRef]
46. Gorski, J.C.; Wang, Z.; Haehner-Daniels, B.D.; Wrighton, S.A.; Hall, S.D. The Effect of Hormone Replacement Therapy on CYP3A Activity. Clin Pharm. 2000, 68, 412–417. [CrossRef]
47. Ginsberg, G.; Hattis, D.; Sonawane, B.; Russ, A.; Banati, P.; Kozlak, M.; Smolenski, S.; Goble, R. Evaluation of Child/Adult Pharmacokinetic Differences from a Database Derived from the Therapeutic Drug Literature. Toxicol. Sci. 2002, 66, 185–200. [CrossRef] [PubMed]
48. Besunder, J.B.; Reed, M.D.; Blumer, J.L. Principles of Drug Biodisposition in the Neonate. A Critical Evaluation of the Pharmacokinetic-Pharmacodynamic Interface (Part I). Clin. Pharmacokinet. 1988, 14, 189–216. [CrossRef]
49. Morselli, P.L. Clinical Pharmacology of the Perinatal Period and Early Infancy. Clin. Pharm. 1989, 17 (Suppl. 1), 13–28. [CrossRef]
50. Kearns, G.L.; Reed, M.D. Clinical Pharmacokinetics in Infants and Children A Reappraisal. Clin. Pharm. 1989, 17 (Suppl. 1), 29–67. [CrossRef]